Abstract
Tenecteplase is a novel fibrinolytic protein bioengineered from human tissue plasminogen activator (alteplase) for the therapy of acute ST-segment elevation myocardial infarction. Specific mutations at three sites in the alteplase molecule result in 15-fold higher fibrin specificity, 80-fold reduced binding affinity to the physiological plasminogen activator inhibitor PAI-1 and 6-fold prolonged plasma half-life (22 vs 3.5 minutes). Consequently, tenecteplase can be administered as a single intravenous bolus of 30–50mg (0.53 mg/kg bodyweight) over 5–10 seconds, in contrast to the 90-minute accelerated infusion regimen of alteplase.
Tenecteplase plasma concentration-time profiles have been obtained from a total of 179 patients with acute myocardial infarction. Tenecteplase exhibited biphasic disposition; the initial disposition phase was predominant with a mean half-life of 17–24 minutes, and the mean terminal half-life was 65–132 min. Over the clinically relevant dose range of 30–50mg, mean clearance (CL) was 105 ml/min. The mean initial volume of distribution V1 was 4.2–6.3L, approximating plasma volume, and volume of distribution at steady state was 6.1–9.9L, suggesting limited extravascular distribution or binding. Bodyweight and age were found to influence significantly both CL and V1. Total bodyweight explained 19% of the variability in CL and 11% of the variability in V1, and a 10kg increase in total bodyweight resulted in a 9.6 ml/min increase in CL. This relationship aided the development of a rationale for the weight-adjusted dose regimen for tenecteplase. Age explained only a further 11% of the variability in CL.
The percentage of patients who achieved normal coronary blood flow was clearly related to AUC. More than 75% of patients achieved normal flow at 90 minutes after administration when their partial AUC2–90 exceeded 320 μg · min/ml, corresponding to an average plasma concentration of 3.6 μg/ml. Systemic exposure to tenecteplase at all times after bolus administration of 30–50mg was higher than for alteplase 100mg.
Tenecteplase has demonstrated equivalent efficacy and improved safety compared with the current gold standard alteplase in a large mortality trial (ASSENT-2). This suggests that the reduced clearance, greater fibrin specificity and higher PAI-1 resistance of tenecteplase allow higher plasma concentrations and thus a more rapid restoration of coronary patency to be attained, while providing a reduction in major non-cerebral bleeding events.
Similar content being viewed by others
Notes
Use of tradenames is for product identification only and does not imply endorsement.
References
Tanswell P, Tebbe U, Neuhaus KL, et al. Pharmacokinetics and fibrin specificity of alteplase during accelerated infusions in acute myocardial infarction. J Am Coll Cardiol 1992; 19: 1071–5
Topol E. An international, randomized trial comparing four thrombolytic strategies for acute myocardial infarction. N Engl J Med 1993; 329: 673–82
Sobel BE. Fibrin specificity of plasminogen activators, rebound generation of thrombin, and their therapeutic implications. Coron Artery Dis 2001; 12: 232–332
Collen D, De Bono DP, Lijnen HR, et al. Development of novel thrombolytic agents: mini-symposium on the role of the fibrinolytic system in the pathophysiology and treatment of thrombosis; 1993 Oct; Leuven. J Intern Med 1994; 236: 433–7
Huber K. Plasminogen activator inhibitor type-I (part two): role for failure of thrombolytic therapy. PAI-1 resistance as a potential benefit for new fibrinolytic agents. J Thrombosis Thrombolysis 2001; 11: 195–202
Keyt B, Paoni N, Refino C, et al. A faster-acting and more potent form of tissue plasminogen activator. Proc Natl Acad Sci U S A 1994; 91(1): 3670–4
Modi NB, Fox NL, Fong WC, et al. Pharmacokinetics and pharmacodynamics of tenecteplase: results from a phase II study in patients with acute myocardial infarction. J Clin Pharmacol 2000; 40: 508–15
Stewart RJ, Fredenburgh JC, Leslie BA, et al. Identification of the mechanism responsible for the increased fibrin specificity of TNK-tissue plasminogen activator relative to tissue plasminogen activator. J Biol Chem 2000; 275: 10112–20
Van de Werf F, Adgey J, Ardissino D, et al. Single bolus tenecteplase compared with front-loaded alteplase in acute myocardial infarction: the ASSENT 2 double-blind randomised trial. Lancet 1999; 354(9180): 716–22
Martin U, Kaufmann B, Neugebauer G. Current clinical use of reteplase for thrombolysis: a pharmacokinetic-pharmacodynamic perspective. Clin Pharmacokinet 1999; 36: 265–76
Kohnert U, Rudolph R, Verheijen JH, et al. Biochemical properties of the kringle-2 and protease domains are maintained in the refolded t-PA deletion variant BM 06.022. Protein Eng 1992; 5: 95–100
GUSTO III Investigators. A comparison of reteplase with alteplase for acute myocardial infarction. N Engl J Med 1997; 337: 1118–23
Dunn CJ, Goa KL. Tenecteplase: a review of its pharmacology and therapeutic efficacy in patients with acute myocardial infarction. Am J Cardiovasc Drugs 2001; 1: 51–66
Van de Werf F, Barron HV, Armstrong PW, et al. Incidence and predictors of bleeding events after fibrinolytic therapy with fibrin-specific agents. Eur Heart J 2001; 22: 2253–61
Wang-Clow F, Fox NL, Cannon CP, et al. Determination of a weight adjusted dose of TNK-tissue plasminogen activator. Am Heart J 2001; 141: 33–50
Gibson CM, Marble SJ. Issues in the assessment of the safety and efficacy of tenecteplase (TNK-tPA). Clin Cardiol 2001; 24: 577–84
Angeja BG, Alexander JH, Chin R, et al. Safety of the weightadjusted dosing regimen of tenecteplase in the ASSENT trial. Am J Cardiol 2001; 88: 1240–5
Collen D, Lijnen HR. Molecular basis of fibrinolysis, as relevant for thrombolytic therapy. Thromb Haemost 1995; 74: 167–71
Lijnen H, Collen D. Strategies for the improvement of thrombolytic agents. Thromb Haemost 1991; 66: 88–110
Bennett WF, Paoni NF, Keyt BA, et al. High resolution analysis of functional determinants on human tissue-type plasminogen activator. J Biol Chem 1991; 266: 5191–201
Parekh RB, Dwek RA, Thomas JR, et al. Cell-type-specific and site-specific N-glycosylation of type I and type II human tissue plasminogen activator. Biochemistry 1989; 28: 7644–62
Noorman F, Rijken DC. Regulation of tissue-type plasminogen activator concentrations by clearance via the mannose receptor and other receptors. Fibrinolysis Proteolysis 1997; 11: 173–86
McCluskey ER, Keyt BA, Refino CJ, et al. Biochemistry, pharmacology and initial clinical experience with TNK-tPA. In: Sasahara AA, Loscalzo J, editors. New therapeutic agents in thrombosis and thrombolysis. New York: Marcel Dekker, Inc., 1997: 475–93
Benedict CR, Refino CJ, Keyt BA, et al. New variant of human tissue plasminogen activator (TPA) with enhanced efficacy and lower incidence of bleeding compared with recombinant human TPA. Circulation 1995; 92: 3032–40
Eppler S, Senn T, Gilkerson E, et al. Pharmacokinetics and pharmacodynamics of recombinant tissue-type plasminogen activator following intravenous administration in rabbits; comparison of three dosing regimens. Biopharm Drug Dispos 1998; 19: 31–8
Modi NB, Eppler S, Breed J, et al. Pharmacokinetics of a slower clearing tissue plasminogen activator variant, TNK-tPA, in patients with acute myocardial infarction. Thromb Haemost 1998; 79: 134–9
Mohler MA, Refino CJ, Chen SA, et al. D-Phe-Pro-Arg-chloromethyl ketone: its potential use in inhibiting the formation of in vitro artifacts in blood collected during tissue-type plasminogen activator thrombolytic therapy. Thromb Haemost 1986; 56: 160–4
Seifried E, Tanswell P. Comparison of specific antibody, D-Phe-Pro-Arg-CH2C1 and aprotinin for prevention of in vitro effects of recombinant tissue-type plasminogen activator on haemostasis parameters. Thromb Haemost 1987; 58: 921–6
Reed BR, Chen AB, Tanswell P, et al. Low incidence of antibodies to recombinant human tissue-type plasminogen activator in treated patients. Thromb Haemost 1990; 64: 276–80
Gibaldi M, Perrier D, editors. Pharmacokinetics. 2nd ed. New York: Marcel Dekker, 1982
Ette EL, Ludden TM. Population pharmacokinetic modeling: the importance of informative graphics. Pharm Res 1995; 12: 1845–55
DeGuzman G, Richarson L, Berleau L, et al. Hepatic uptake and processing of TNK-tPA [abstract]. Pharm Res 1995; 123: 332
Tanswell P, Stassen JM, Platz S. Regulatory submission to EMEA. Metalyse® (tenecteplase): expert report on the toxico-pharmacological documentation. Biberach: Boehringer Ingelheim, 1999. (Data on file)
Keyt BA, Berleau LT, Nguyen HV, et al. Radioiodination of the active site of tissue plasminogen activator: a method for radiolabeling serine proteases with tyrosylprolyarginyl chloromethyl ketone. Anal Biochem 1992; 206: 73–83
Bakhit C, Lewis D, Busch U, et al. Biodisposition and catabolism of tissue-type plasminogen activator in rats and rabbits. Fibrinolysis 1988; 2: 31–6
Lucore CL, Sobel BE. Interactions of tissue-type plasminogen activator with plasma inhibitors and their pharmacologic implications. Circulation 1988; 77: 660–9
Tanswell P, Seifried E, Stang E, et al. Pharmacokinetics and hepatic catabolism of tissue-type plasminogen activator. Arzneimittel Forschung 1991; 41: 1310–9
Krause J. Hepatic catabolism of tissue-type plasminogen activator (t-PA), its variants, mutants and hybrids. Fibrinolysis 1988; 2: 133–42
Bu G, Williams S, Strickland DK, et al. Low density lipoprotein receptor-related protein/alpha(2)-macroglobulin receptor is an hepatic receptor for tissue-type plasminogen activator. Proc Natl Acad Sci U S A 1992; 89: 7427–31
Smedsrod B, Einarsson M. Clearance of tissue plasminogen activator by mannose and galactose receptors in the liver. Thromb Haemost 1990; 63: 60–6
Tanswell P, Heinzel G, Greischel A, et al. Nonlinear pharmacokinetics of tissue-type plasminogen activator in three animal species and isolated perfused rat liver. J Pharmacol Exp Ther 1990; 255: 318–24
Cannon CP, Gibson CM, McCabe CH, et al. TIMI 10B Investigators. TNK tissue plasminogen activator compared with front-loaded alteplase in acute myocardial infarction: results of the TIMI 10B trial. Circulation 1998; 98: 2805–14
Van de Werf F, Cannon CP, Luyten A, et al. Safety assessment of single-bolus administration of TNK tissue-plasminogen activator in acute myocardial infarction: the ASSENT-1 trial. The ASSENT-1 Investigators. Am Heart J 1999; 137: 786–91
Tanswell P, Seifried E, Su CAPF, et al. Pharmacokinetics and systemic effects of tissue-type plasminogen activator in normal subjects. Clin Pharmacol Ther 1989; 46: 155–62
Cannon CP, McCabe CH, Gibson CM, et al. TNK-tissue plasminogen activator in acute myocardial infarction: results of the Thrombolysis In Myocardial Infarction (TIMI) 10A doseranging trial. Circulation 1997; 95: 351–6
Van de Werf F, ASSENT-3 investigators. Efficacy and safety of tenecteplase in combination with enoxaparin, abciximab, or unfractionated heparin: the ASSENT—3 randomised trial in acute myocardial infarction. Lancet 2001; 358: 605–13
Sulikowski T, Patson PA. The inhibition of TNK-tPA by C1inhibitor. Blood Coagul Fibrinolysis 2001; 12: 75–7
Van Griensven JMT, Koster RW, Burggraaf J, et al. Effects of liver blood flow on the pharmacokinetics of tissue-type plasminogen activator (alteplase) during thrombolysis in patients with acute myocardial infarction. Clin Pharmacol Ther 1998; 63: 39–47
Sobel BE, Gross RW, Robison AK. Thrombolysis, clot selectivity, and kinetics. Circulation 1984; 70: 160–4
Thomaseth K, Boniollo B. Simulation of plasmatic enzymatic reactions during thrombolytic therapy with recombinant tissue-type plasminogen activator: from in vitro knowledge to new assumptions in vivo. Simulation 1996; 66: 219–28
Sharma A, Jusko WJ. Characteristics of indirect pharmacodynamic models and application to clinical drug responses. Br J Clin Pharmacol 1998; 48: 229–39
Hoylaerts M, Rijken DC, Lijnen HR, et al. Kinetics of the activation of plasminogen by human plasminogen activator: role of fibrin. J Biol Chem 1982; 257: 2912–9
Lee LV, Ewald GA, McKenzie CR, et al. The relationship of soluble fibrin and cross-linked fibrin degradation products to the clinical course of myocardial infarction. Arterioscler Thromb Vasc Biol 1997; 17: 628–33
Seifried E, Tanswell P, Rijken DC, et al. Fibrin degradation products are not specific markers for thrombolysis in myocardial infarction. Lancet 1987; II: 333–4
Walker JB, Nesheim ME. The molecular weights, mass distribution, chain composition, and structure of soluble fibrin degradation products released from a fibrin clot perfused with plasmin. J Biol Chem 1999; 274: 5201–12
Binbrek A, Rao N, Absher M, et al. The relative rapidity of recanalization induced by recombinant tissue-type plasminogen activator (r-tPA) and TNK-tPA, assessed with enzymatic methods. Coron Artery Dis 2000; 11(5): 429–35
Ohman EM, Armstrong PW, White HD, et al. GUSTO-III Investigators. Risk stratification with a point-of-care cardiac troponin T test in acute myocardial infarction. Am J Cardiol 1999; 84: 1281–6
Antman EM, Tanasijevic MJ, Thompson B, et al. Cardiac specific troponin I levels to predict the risk of mortality in patients with acute coronary syndromes. N Engl J Med 1996; 335: 1342–9
The TIMI study group. The thrombolysis in myocardial infarction (TIMI) trial. N Engl J Med 1985; 312: 932–6
Gibson CM, Cannon CP, Daley WL, et al. TIMI Frame Count: a quantitative method of assessing coronary artery flow. Circulation 1996; 93: 879–88
Mehta SR, Eikeboom JW, Yusuf S. Risk of intracranial haemorrhage with bolus vs infusion thrombolytic therapy: a metaanalysis. Lancet 2000; 356: 449–54
Liao WC, Beierle FA, Stouffer BC, et al. Single bolus regimen of lanoteplase (nPA) in acute myocardial infarction: pharmacokinetic evaluation from the InTIME-1 study. Circulation 1997; 96 Suppl. I: 1260–1
Gibson CM, Cannon CP, Murphy SA, et al. Weight-adjusted dosing of TNK-tissue plasminogen activator and its relation to angiographic outcomes in the thrombolysis in myocardial infarction 10 B trial. Am J Cardiol 1999; 84: 976–80
Hammann GF, Okada Y, del Zoppo GJ. Hemorrhagic transformation and microvascular integrity during focal cerebral ischemia/reperfusion. J Cereb Blood Flow Metab 1996; 16: 1373–8
Acknowledgements
We wish to thank Drs K. Schleenhain and G. Heusel for expert help in the preparation of the manuscript. The authors are or were employed by Boehringer Ingelheim or Genetech, Inc. These companies sponsored the clinical trials described in the review and also manufacture and market tenecteplase.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Tanswell, P., Modi, N., Combs, D. et al. Pharmacokinetics and Pharmacodynamics of Tenecteplase in Fibrinolytic Therapy of Acute Myocardial Infarction. Clin Pharmacokinet 41, 1229–1245 (2002). https://doi.org/10.2165/00003088-200241150-00001
Published:
Issue Date:
DOI: https://doi.org/10.2165/00003088-200241150-00001